Sarepta's Eteplirsen Is Centerpiece Of Senate Hearing On Expanded Access

Witnesses call for political pressure on FDA to approve the Duchenne drug; patients and advocates also urge general approval reciprocity with Europe and incentives for pediatric trials; agency was not invited to testify.

One of the witnesses at a Senate hearing on how to improve patient access to experimental treatments was six year-old Jordan McLinn who said, "Please say yes for the drug."

Although the name of the drug was not mentioned it is Sarepta Therapeutics Inc

More from United States

More from North America